Patents matching “formulation”

US 11285210

Buffer formulations for enhanced antibody stability

Outlook Therapeutics, Inc. · Granted Mar 29, 2022 · Expires Mar 24, 2042

US 11278493

Ophthalmic formulations providing durable ocular lubrication

ETERNATEAR, INC. · Granted Mar 22, 2022 · Expires Mar 17, 2042

US 11278521

GAS5 binding compounds, formulations, and uses thereof

THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS OFFICE OF GENERAL COUNSEL—PSG IV (024) · Granted Mar 22, 2022 · Expires Mar 17, 2042

US 11266611

More potent and less toxic formulations of epinephrine and methods of medical use

Eton Pharmaceuticals, Inc. · Granted Mar 8, 2022 · Expires Mar 3, 2042

US 11266641

Formulations of a somatostatin modulator

CRINETICS PHARMACEUTICALS, INC. · Granted Mar 8, 2022 · Expires Mar 3, 2042

US 11266649

Pharmaceutical formulations

Corvus Pharmaceuticals, Inc. · Granted Mar 8, 2022 · Expires Mar 3, 2042

WO 2022029639

FORMULATIONS PHARMACEUTIQUES AMÉLIORÉES COMPRENANT DES INHIBITEURS DE PI3K

BERLIN CHEMIE AG [DE] · Granted Feb 10, 2022 · Expires Feb 5, 2042

US 11241499

Human serum albumin in formulations

REGENERON PHARMACEUTICALS, INC. · Granted Feb 8, 2022 · Expires Feb 3, 2042

US 11229702

High concentration formulations of adalimumab

Coherus BioSciences, Inc. · Granted Jan 25, 2022 · Expires Jan 20, 2042

US 11229687

TPP-1 formulations and methods for treating CLN2 disease

BIOMARIN PHARMACEUTICAL INC. · Granted Jan 25, 2022 · Expires Jan 20, 2042

US 11219608

Triple combination formulation for treatment of chronic pain

Northwestern University · Granted Jan 11, 2022 · Expires Jan 6, 2042

US 11213497

Antibiofilm formulations

Arizona Board of Regents on Behalf of Northern Arizona University · Granted Jan 4, 2022 · Expires Dec 30, 2041

US 11202770

Liquid tasimelteon formulations and methods of use thereof

VANDA PHARMACEUTICALS INC. · Granted Dec 21, 2021 · Expires Dec 16, 2041

US 11197812

Cosmetic formulations for topical applications containing erythropoietin-derived molecules

ASC REGENITY LIMITED · Granted Dec 14, 2021 · Expires Dec 9, 2041

US 11197916

Lyophilized recombinant VWF formulations

Takeda Pharmaceutical Company Limited · Granted Dec 14, 2021 · Expires Dec 9, 2041

US 11197869

Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

Windtree Therapeutics, Inc. · Granted Dec 14, 2021 · Expires Dec 9, 2041

US 11197847

Isoxazoline parasiticide formulations and methods for treating blepharitis

Tarsus Pharmaceuticals, Inc. · Granted Dec 14, 2021 · Expires Dec 9, 2041

US 11197821

Formulations for treatment of dry eye disease

Aldeyra Therapeutics, Inc. · Granted Dec 14, 2021 · Expires Dec 9, 2041

US 11191821

Peptide vaccine formulations and use thereof for inducing an immune response

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 7, 2021 · Expires Dec 2, 2041

US 11191837

Recombinant VWF formulations

Takeda Pharmaceutical Company Limited · Granted Dec 7, 2021 · Expires Dec 2, 2041

US 11191774

Drug formulations for cancer treatment

The Regents of the University of California · Granted Dec 7, 2021 · Expires Dec 2, 2041

US 11191813

Lyophilized recombinant VWF formulations

Takeda Pharmaceutical Company Limited · Granted Dec 7, 2021 · Expires Dec 2, 2041

US 11180517

Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

Compass Pathfinder Limited · Granted Nov 23, 2021 · Expires Nov 18, 2041

US 11173118

Emulsion formulations of an NK-1 receptor antagonist and uses thereof

Heron Therapeutics, Inc. · Granted Nov 16, 2021 · Expires Nov 11, 2041